RT Journal Article
SR Electronic
T1 Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases
JF BJGP Open
JO BJGP Open
FD Royal College of General Practitioners
SP BJGPO.2021.0083
DO 10.3399/BJGPO.2021.0083
A1 Toby Peter Speirs
A1 Nicole Tuffin
A1 Finlay Mundy-Baird
A1 Helena Sakota
A1 Sarah Mulholland
A1 Michelle Westlake
A1 Max Lyon
A1 Andrew R Medford
A1 Charles Sharp
A1 Michael Darby
A1 Mahableshwar Albur
A1 Francis Keeley
A1 Helena Burden
A1 Charlie Kenward
A1 Elizabeth Jonas
A1 Shaney Barratt
A1 Huzaifa I Adamali
YR 2021
UL http://bjgpopen.org/content/early/2021/10/20/BJGPO.2021.0083.abstract
AB Background Long-term nitrofurantoin (NF) treatment can result in pulmonary and hepatic injury. Current guidelines do not outline the type or frequency of monitoring required for detection of these injuries.Aim To assess 1) awareness of NF complications among prescribers; 2) monitoring practice; and 3) to describe the pulmonary sequelae of NF-related complications.Design & setting Evaluation of prescribing habits by questionnaires and review of GP databases, and case-note review in secondary care.Method The following study procedures were undertaken: 1) an electronic questionnaire was distributed to prescribers, interrogating prescribing and monitoring practices, and awareness of complications; 2) an analysis was undertaken (June–July 2020) of NF monitoring among GPs in the local clinical commissioning group (CCG); and 3) a case review was carried out of patients diagnosed with NF-induced interstitial lung disease (NFILD) at the interstitial lung disease (ILD) centre (2014–2020).Results A total of 125 prescribers of long-term NF responded to the questionnaire (82.4% GPs; 12.0% urologists). Many were unaware of the potential for liver (42.4%) and lung (28.0%) complications; 40.8% and 52.8% never monitored for these, respectively. Only 53.3% of urologists believed themselves responsible for arranging monitoring, while nearly all GPs believed this to be the prescriber’s responsibility (94.2%). One-third of all responders considered current British National Formulary (BNF) guidelines 'not at all sufficient/clear', with mean clarity scoring of 2.2/5. Among patients with NFILD (n = 46), NF had been prescribed most often (69.6%) for treatment of recurrent UTI and 58.6% (n = 27) were prescribed for >6 months. On withdrawal of the medication 61.4% displayed resolution (completely or minimal fibrosis), while 15.9% of patients had progressive lung fibrosis.Conclusion NF can cause marked or irreversible lung complications and there is currently a shortfall in awareness and monitoring. Existing monitoring guidelines should be augmented.